HP515 Phase I Clinical Trial Results Presented at EASL Congress 2026
Recently, the abstract of the Phase I clinical trial of HP515, a THR-β agonist independently developed by Hinova Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), was presented as a poster at the EASL Congress 2026 (European Association for the Study of the Liver Congress 2026).
As a premier global academic event in the field of liver diseases, this achievement was selected for presentation at the congress, fully demonstrating the Company's R&D capabilities in innovative drugs for metabolic dysfunction-associated steatohepatitis (MASH), and marking international recognition of the product's development progress by the global academic community.
About the Congress
The EASL Congress is the world's largest, most academically authoritative, and most influential top-tier academic conference in the field of hepatology, bringing together physicians, scientists, healthcare professionals, patients, and industry partners from around the globe. It serves as a core bellwether and strategic platform for guiding the development of global liver disease disciplines, setting industry standards, and promoting clinical and industrial progress.
The congress is hosted by the European Association for the Study of the Liver (EASL), founded in 1966, a prestigious medical institution dedicated to liver research, clinical practice in liver disease diagnosis and treatment, and providing professional academic education to practitioners worldwide in the field of liver diseases.
About HP515
HP515 is an oral, highly selective THR-β (thyroid hormone receptor beta) agonist independently developed by the Company. HP515 tablets directly act on THR-β to activate downstream gene transcription, improving metabolic dysfunction-associated steatohepatitis by enhancing hepatocellular lipid metabolism, promoting hepatic fat metabolism, and reducing lipotoxicity. HP515 received approval from China's National Medical Products Administration (NMPA) in August 2024 for the treatment of metabolic steatohepatitis (MASH), and received approval from the U.S. Food and Drug Administration (FDA) in September 2024 for the treatment of MASH.
The Company has completed the Phase I clinical trial of HP515, which was a clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of single and multiple ascending doses of HP515 in healthy subjects. The Phase I clinical trial results of HP515 showed that HP515 met expectations in terms of safety, tolerability, pharmacokinetics, and pharmacodynamics.
Under conditions of 40 mg, 60 mg, and 80 mg once-daily dosing for 14 consecutive days, SHBG (sex hormone-binding globulin) showed a significant dose-dependent increase from placebo-corrected baseline. At the 80 mg dose, SHBG increased by 176.25% after 14 days of dosing, indicating that HP515 exerts its pharmacological effects through activation of the endogenous THR-β receptor. Meanwhile, several lipid parameters showed significant improvement following HP515 treatment: LDL-C (low-density lipoprotein cholesterol), TC (total cholesterol), and ApoB (apolipoprotein B) demonstrated significant dose-dependent reductions from baseline. At the 80 mg dose, LDL-C decreased by 34.48%, TC decreased by 22.91%, and ApoB decreased by 35.91%.
Based on the positive results from the Phase I clinical trial, the Company is actively advancing the Phase IIa clinical trial of HP515, which is a clinical trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of HP515 in participants with metabolic dysfunction-associated fatty liver disease. The Phase IIa clinical trial of HP515 has completed enrollment of all participants and has achieved positive interim analysis results. As of the date of this release, no products targeting the same indication have been approved for marketing in China.
Disclaimer:
1. This article is intended solely to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not promotional material. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.
2. The information contained herein is derived from relevant research reports and clinical data and is for reference only. Please follow the guidance of physicians or other qualified healthcare professionals.
3. Any information involving unapproved products refers to assets still in development or clinical trials and involves uncertainties. Final outcomes are subject to approval by the National Medical Products Administration.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D


